Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab ...Middle East

HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1,...

Hence then, the article about akeso advances io 2 0 adc 2 0 strategy with phase ii initiation of novel adcs combined with ivonescimab and cadonilimab was published today ( Wednesday 25/03/2026 - 05:55 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab )

Also on site :

• HBO Max Developing Pair Of Euro Medical Dramas & Taking Creative Cues From ‘The Pitt’
• Long lines, unpaid TSA workers: Experts say US air travel system in crisis
• Explosion, fire at Erbil high-rise amid Iranian attacks